Psychedelics beyond medicine: Treatment, enhancement, hype, consent, and the limits of medicalization
Open Access
- 8 September 2025
- journal article
- Published by Taylor & Francis in Philosophical Psychology
- Vol. 38 (7) , 3340-3383
Abstract
No abstract availableFunding Information
- Novo Nordisk Fonden
- Inter-CeBIL Programme (NNF23SA0087056)
- Wellcome Trust (221152/Z/20/Z)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (222239)
- Carlsbergfondet
- Wellcome Trust
- Discovery Research Platform for Transformative Inclusivity in Ethics and Humanities Research
- Wellcome Trust
- National Institute for Health and Care Research (NIHR203316)
- HoPE
This publication has 199 references indexed in Scilit:
- Psychedelic Therapy Scrutinized by FDA Advisory Committee?JAMA, 2024
- State-Regulated Psychedelics on a Collision Course With FDAJAMA, 2023
- Single-Dose Psilocybin Treatment for Major Depressive DisorderJAMA, 2023
- Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted TherapiesJAMA Psychiatry, 2023
- Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research LandscapeJAMA Psychiatry, 2023
- Psychedelic Drug Legislative Reform and Legalization in the USJAMA Psychiatry, 2023
- Preparing for the Bursting of the Psychedelic Hype BubbleJAMA Psychiatry, 2022
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderJAMA Psychiatry, 2022
- Two Models of Legalization of Psychedelic SubstancesJAMA, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021